Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Gore

Showing results (151-160 of 157) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 157 results.
British Journal of Cancer|March 20, 2014
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancerR M Glasspool, R Brown, M E Gore, et al.
Human Gene Therapy|June 12, 1999
Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanomaK Palmer, J Moore, M Everard, et al.
British Journal of Cancer|July 14, 2011
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studiesT Eisen, R Marais, A Affolter, et al.
British Journal of Cancer|July 14, 2011
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanomaS O'Day, A Pavlick, C Loquai, et al.
Investigational New Drugs|May 11, 2002
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studiesJ H M Schellens, B Heinrich, M Lehnert, et al.
British Journal of Cancer|June 19, 2015
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinomaM E Gore, C Szczylik, C Porta, et al.
British Journal of Cancer|December 4, 1998
Chemotherapy for ovarian cancer--a consensus statement on standard practiceM Adams, A H Calvert, J Carmichael, et al.
Pageof 16

Showing results (151-160 of 157) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 157 results.
British Journal of Cancer|March 20, 2014
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancerR M Glasspool, R Brown, M E Gore, et al.
Human Gene Therapy|June 12, 1999
Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanomaK Palmer, J Moore, M Everard, et al.
British Journal of Cancer|July 14, 2011
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studiesT Eisen, R Marais, A Affolter, et al.
British Journal of Cancer|July 14, 2011
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanomaS O'Day, A Pavlick, C Loquai, et al.
Investigational New Drugs|May 11, 2002
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studiesJ H M Schellens, B Heinrich, M Lehnert, et al.
British Journal of Cancer|June 19, 2015
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinomaM E Gore, C Szczylik, C Porta, et al.
British Journal of Cancer|December 4, 1998
Chemotherapy for ovarian cancer--a consensus statement on standard practiceM Adams, A H Calvert, J Carmichael, et al.
Pageof 16